- US12600722utility2026Tetracyclic Compounds as DGK Inhibitors0 cites
- US12600723utility2026Tetracyclic Compounds as DGK Inhibitors0 cites
- US12600717utility2026Tricyclic Compounds as Inhibitors of KRAS0 cites
- US12589096utility2026Ruxolitinib Formulation for Reduction of Itch in Atopic Dermatitis0 cites
- US12552804utility2026Tricyclic Heterocycles as FGFR Inhibitors0 cites
- US12551485utility2026Topical Formulations of Ruxolitinib with an Organic Amine Ph Adjusting Agent for Treatment of Skin Diseases0 cites
- US12552792utility2026Solid Forms of an FGFR Inhibitor and Processes for Preparing the Same0 cites
- US12498382utility2025Biomarkers for Vitiligo0 cites
- US12491244utility2025Pharmaceutical Combinations for Treating Tumor Comprising Anti-cd19 Antibody and Natural Killer Cell0 cites
- US12479851utility2025Process and Intermediates for Preparing a JAK Inhibitor0 cites
- US12473286utility2025Salts of an FGFR Inhibitor0 cites
- US12466815utility2025Carboxamide Compounds and Uses Thereof0 cites
- US12466822utility2025Heterocyclic Compounds as Immunomodulators0 cites
- US12466828utility2025Bicyclic Amines as CDK2 Inhibitors0 cites
- US12459943utility2025Crystalline Solid Forms of a BET Inhibitor0 cites
- US12440495utility2025Combination Therapy for Treatment of Myeloproliferative Neoplasms0 cites
- US12441727utility2025Tricyclic Compounds as Inhibitors of KRAS0 cites
- US12441731utility2025Pyrazolopyrimidine Compounds and Uses Thereof0 cites
- US12441742utility2025Naphthyridine Compounds as Inhibitors of KRAS0 cites
- US12428420utility2025Tricyclic Heterocycles as FGFR Inhibitors0 cites
Page 1 of 8Next →